XTL Biopharmaceuticals Ltd. said that a Phase II study of its bicifadine for the treatment of diabetic nerve pain did not meet any of its objectives, causing the company's shares to fall 94.4 percent. (BioWorld Today) Read More
No Abstract BioWorld Today CorrespondentGanymed Pharmaceuticals AG landed one of Europe's landmark private equity deals of 2008, a €65 million (US$82.2 million) fourth financing round that will fund preclinical and early clinical development of a broad pipeline of its cancer-specific antibody therapies in multiple oncology indications. Read More
